Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,247.96
(
0.54%
)
US TECH 100
26,858.40
(
0.56%
)
Dow Jones
49,652.14
(
0.00%
)
Brent Oil
108.48
(
-1.70%
)
Bitcoin
78,419.99
(
2.74%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 50
Posts 5533
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: DewDiligence post# 243598

Thursday, 08/25/2022 7:50:11 PM

Thursday, August 25, 2022 7:50:11 PM

Post# of 257473
Gsk is using a half dose of the adjuvant that is in Shingrix so we will see about tolerability
I’m inclined to agree w you on efficacy. After all the JNJ data has been out and it would be odd to characterize data as “exceptional” if you weren’t at least close to the JNJ efficacy benchmark
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today